Applied Therapeutics, Inc. (APLT)
- Previous Close
4.8300 - Open
4.8000 - Bid 4.6900 x 100
- Ask 4.7400 x 200
- Day's Range
4.7005 - 5.0000 - 52 Week Range
0.9280 - 9.3900 - Volume
724,354 - Avg. Volume
1,849,195 - Market Cap (intraday)
501.904M - Beta (5Y Monthly) 1.81
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4200 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.60
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
www.appliedtherapeutics.comRecent News: APLT
Performance Overview: APLT
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLT
Valuation Measures
Market Cap
501.37M
Enterprise Value
452.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.92
Price/Book (mrq)
--
Enterprise Value/Revenue
45.26
Enterprise Value/EBITDA
-7.05
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.56%
Return on Equity (ttm)
--
Revenue (ttm)
9.99M
Net Income Avi to Common (ttm)
-119.76M
Diluted EPS (ttm)
-1.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
49.9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
7.74M